Vancomycin

MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)

Retrieved on: 
onsdag, maj 15, 2024
Research, Infectious Diseases, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, Other Science, Science, Ulcerative colitis, DDW, Patient, MRM, Washington Convention Center, Treatment, DSM-IV codes, Dysbiosis, Efficacy, CNS, Gene, Walter, Inflammatory Bowel Diseases, Safety, Poster, Abstract, Vancomycin, Gastrointestinal disease, Therapy, Inflammation, MES, Pharmaceutical industry

Stool consistency significantly improved in the MH002 treatment group as from week 2 (p=0.006; 1-sided Student t-test).

Key Points: 
  • Stool consistency significantly improved in the MH002 treatment group as from week 2 (p=0.006; 1-sided Student t-test).
  • At the end of the eight-week period, 18% of subjects achieved clinical remission compared to 0% of the placebo group (Per-protocol analysis).
  • Furthermore, microbiome restoration occurred in parallel with clinical effects, and differential gene expression analysis showed downregulation of genes involved in inflammation.
  • These findings were in line with the mode-of-action of MH002 and linked to restoration of intestinal dysbiosis, mucosal integrity, and immune homeostasis.

InsightRX Continues Momentum in Precision Dosing with Client Growth, New Scientific Breakthroughs

Retrieved on: 
tisdag, maj 14, 2024
Pharmacology, Vantage, Patient, Hospital, Organization, Clinical trial, Drug development, SAN, Growth, Pharming, Vancomycin, Personalized medicine, Obesity, BMI, Pharmaceutical industry

SAN FRANCISCO, May 14, 2024 /PRNewswire/ -- InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – continues to build momentum in the health systems and life sciences markets in 2024, with numerous technological and scientific breakthroughs achieved in collaboration with its clients.

Key Points: 
  • InsightRX delivers a precision-dosing platform that uses quantitative methods to improve drug dosing practices, combining patient-level and population-level continuous learning to maximize therapeutic benefits for patients.
  • InsightRX recommends use of the Modified Thomson model as the default model for patients with a BMI
  • InsightRX recommends use of this new model as the default model for patients with a BMI > 40.
  • Increasingly, drug developers are turning to InsightRX for its cloud software platform and clinical pharmacology services.

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Retrieved on: 
torsdag, maj 2, 2024
Infection, Clostridioides difficile infection, Congress, University, University of Houston, Vancomycin, Professor, Poster, Recurrence, IIIC, Disease, DNA, Patient, Treatment, Microbiology, Doctor of Pharmacy, Diarrhea, CDI, Fidaxomicin, Clostridioides difficile, Houston Community College, Pharmaceutical industry

The presentation included additional analyses of clinical and microbiological data from the Phase 2b Segment of the trial.

Key Points: 
  • The presentation included additional analyses of clinical and microbiological data from the Phase 2b Segment of the trial.
  • Commenting on his presentation, Dr. Garey stated: "This randomized, active-controlled study showed ibezapolstat was comparable to vancomycin in achieving clinical cure in patients with mild-to-moderate CDI.
  • The presentation and poster are available on the Acurx Pharmaceuticals website following their respective presentations at the conference.
  • www.acurxpharma.com
    The complete Phase 2 results are being prepared for submission to a prominent scientific journal.

DoseMe Expands Global Footprint as Premier Hospitals and Cancer Centers across Australia Continue to Adopt Bayesian Dosing

Retrieved on: 
onsdag, april 17, 2024
Software, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Health Technology, Technology, Mortality, Austin Hospital, Royal North Shore Hospital, Aminoglycoside, Hospital, Risk, Vancomycin, Safety, Research, Royal Perth Hospital, Attention, Acute kidney injury, HITRUST, Patient, Toxicity, AKI, Medicine, Algorithm, Pharmacist, Growth, Pharmaceutical industry

DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.

Key Points: 
  • DoseMe , a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Australia.
  • The precision dosing software has informed over 400,000 dosing decisions, benefiting more than 10,000 patients and gaining the trust of over 1,000 clinicians nationwide.
  • “It is exciting to see the global demand around precision dosing, with Australia continuing to be a trailblazer,” said Paul Edwards, CEO of DoseMe.
  • This surge in clientele was boosted by strategic partnerships worldwide, underscoring DoseMe's commitment to global expansion and continuous innovation to deliver advanced precision dosing.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
torsdag, april 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

OsteoRemedies® Obtains Expanded Indications for SPECTRUM® Dual Antibiotic Bone Cement

Retrieved on: 
tisdag, april 23, 2024
FDA, Patient, Research, MRSA, Infection, Vancomycin

MEMPHIS, Tenn., April 23, 2024 /PRNewswire/ -- OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement.

Key Points: 
  • MEMPHIS, Tenn., April 23, 2024 /PRNewswire/ -- OsteoRemedies® LLC, an orthopedic company focused on providing simple solutions to complex disorders, has announced FDA clearance for expanded indications for the SPECTRUM® GV Bone Cement.
  • Initially launched in 2018, SPECTRUM® GV Bone Cement is the first commercially available dual antibiotic bone cement on the US market.
  • Containing both vancomycin and gentamicin, SPECTRUM® GV Bone Cement prevents bacterial adhesion of susceptible organisms, intermediate-resistant, and methicillin-resistant staphylococcal infections.
  • From a mechanical performance perspective, testing of SPECTRUM® GV Bone Cement has been compared to commercially available single antibiotic bone cements and found to have substantially equivalent mechanical integrity.

Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

Retrieved on: 
tisdag, april 9, 2024
Biotechnology, Pharmaceutical, Health, Infectious Diseases, Hospitals, Health Technology, Genetics, Clinical Trials, Congress, Midwestern University, BCPS, Doctor of Pharmacy, Professor, AUC, Patient, Big data, Vancomycin, Safety, ESCMID, ECCMID, European, Infection, Pharmaceutical industry

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Key Points: 
  • ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.
  • Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS , Chief Strategy and Science Officer and Paul Sabourenkov , Lead Bioinformatician at DoseMe.
  • What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
  • Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.

FDA Approves New Antibiotic for Three Different Uses

Retrieved on: 
onsdag, april 3, 2024
Daptomycin, Research, Hypersensitivity, Hypokalemia, Fungal infection, Aztreonam, Dizziness, Pneumonia, Survival, Dysgeusia, Potassium, Seizure, Abdominal pain, Dietary supplement, CABP, Headache, Patient, Public, Insomnia, Bacterial pneumonia, Food and Drug Administration, Animal, Bilirubin, Diarrhea, History, Mortality, Vancomycin, Leukopenia, Clostridioides, Human services, Injection site reaction, Nausea, Rash, Priority review, Bronchopneumonia, Skin, Fever, Heated tobacco product, Ceftriaxone, Safety, SAB, Anemia, Division, Phlebitis, Cosmetics, Vaccine, Infection, Food, Vomiting, Blood, Multimedia, FDA, Periodic breathing, ABSSSI, Pharmaceutical industry

"The FDA will continue our important work in this area as part of our efforts to protect the public health."

Key Points: 
  • "The FDA will continue our important work in this area as part of our efforts to protect the public health."
  • Zevtera's efficacy in treating SAB was evaluated in a randomized, controlled, double-blind, multinational, multicenter trial .
  • In the trial, researchers randomly assigned 390 subjects to receive Zevtera (192 subjects) or daptomycin plus optional aztreonam [the comparator] (198 subjects).
  • A total of 69.8% of subjects who received Zevtera achieved overall success compared to 68.7% of subjects who received the comparator.

New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT

Retrieved on: 
fredag, februari 16, 2024
Carbon, Hospital, Watt, Mining, News, Somnolence, DNX, Bacteria, FINRA, Global X ETFs, Patient, Corporation, BTC, POW, Biopharmaceutical, Television, Carbon footprint, Pain, Wind, CDI, Vancomycin, Fox Business, Ecosystem, SBP, Interview, Miner, Partnership, Woman, Nursing, Sleep, ESG, Insomnia, Business, Decentralization, EnergySolutions, Fibromyalgia, Tonix Pharmaceuticals, MD, Sustainability, FDA, Patent, SBC, Food, Tongue, United States patent law, Medicine, Headache, Publication, Cryptocurrency

New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:

Key Points: 
  • New to The Street's Episode 556 line-up features the following five (5) Corporate interviews:
    2).
  • Tonix's new drug, called Tonmya™, is a new class of medicine that controls pain in those who have fibromyalgia.
  • Fibromyalgia is common in women who have been unsuccessful in finding current marketplace drugs limited in the treatment success.
  • Clinical studies have shown that Tonmya™ can eliminate most pain, enhance sleep, and diminish fatigue in patients.

DoseMe Expands Vancomycin Hemodialysis Model

Retrieved on: 
torsdag, februari 15, 2024
Technology, Health Technology, Software, Biotechnology, Health, Pharmaceutical, General Health, Data Management, Artificial Intelligence, BCPS, TDM, Toxicity, Obesity, HD, Dialysis, Vancomycin, Doctor of Pharmacy, Risk, Medicine, Patient, IHD, Medical device

DoseMe , a leading provider of model informed precision dosing, today announced the availability of its new Vancomycin Hemodialysis (HD) model.

Key Points: 
  • DoseMe , a leading provider of model informed precision dosing, today announced the availability of its new Vancomycin Hemodialysis (HD) model.
  • The vancomycin hemodialysis (HD) model enables personalized dosing that reduces the necessity for multiple blood draws for vancomycin levels.
  • Implementing this optimized model could further enhance precision and personalization of vancomycin therapy in hemodialysis patients.
  • Overall, integrating the optimized model with DoseMeRx has potential to improve vancomycin dosing accuracy and outcomes in the hemodialysis population.